Stocks Health care BIOA
NASDAQ · Health careBioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. brought in $8.6M of revenue over the twelve months to September 30, 2026. It posted a net loss of $107.8M. In fiscal 2025 capital spending exceeded operating cash flow by $82.3M. At September 30, 2026 it held $52.7M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 5, 2026.
Key facts about BioAge Labs, Inc.
- Net worth
- BioAge Labs, Inc. has a market value (market cap) of $261.2M at the latest share price, and shareholders' equity of $346.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $9M, with a net loss of $80.6M. Over the 12 months to September 30, 2026: revenue $8.6M, net loss $107.8M.
- Cash flow
- In fiscal 2025 operations used $81.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 5, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- BioAge Labs, Inc.'s next report is expected around March 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What BioAge Labs, Inc. does
BioAge Labs, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BIOA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $9M | -$80.6M | -$2.24 | -$82.3M |
| 2024 | $0 | -$71.1M | -$6.63 | -$51.9M |
| 2024 | n/a | -$63.9M | -$38.17 | -$37.5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BIOA ranks in Health care
Latest SEC filings
What BioAge Labs, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 5, 2026Quarterly report 10-Q · period to September 30, 2026Revenue fell 85% to $298K versus the same quarter last year; diluted EPS -$0.73 versus -$0.56.
- November 5, 2026
- October 2, 2026Other event 8-K
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 1.6% to $2.5M versus the same quarter last year; diluted EPS -$0.58 versus -$0.60.
- August 5, 2026
- June 12, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 8, 2026
Insider trades
What the people running BioAge Labs, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| June 30, 2026 | Barton ShanePrincipal Accounting Officer | Exercised options | 4,290 | $46.5K |
| June 30, 2026 | Barton ShanePrincipal Accounting Officer | Exercised options | 4,000 | $33.6K |
| June 30, 2026 | Barton ShanePrincipal Accounting Officer | Exercised options | 4,065 | $17.5K |
| June 30, 2026 | Barton ShanePrincipal Accounting Officer | Exercised options | 7,861 | $34.4K |
| June 30, 2026 | Barton ShanePrincipal Accounting Officer | Soldpre-planned (10b5-1) | 20,216 | $509.2K |
| June 29, 2026 | Barton ShanePrincipal Accounting Officer | Exercised options | 9,301 | $100.9K |
| June 29, 2026 | Barton ShanePrincipal Accounting Officer | Exercised options | 7,261 | $60.9K |
| June 29, 2026 | Barton ShanePrincipal Accounting Officer | Exercised options | 8,958 | $38.5K |
Who owns BIOA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Marc Andreessen13D, may seek influence with 9 related filers | 9% | October 4, 2024 |
| Kristen Fortney13G, passive | 7.2% | February 13, 2026 |
| Dr. James I. Healy ("Healy")13D, may seek influence with 4 related filers | 6.7% | September 30, 2024 |
| Cormorant Asset Management, LP13G, passive with 1 related filers | 5.38% | August 14, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 151 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| a16z Capital Management, L.L.C. | 3,233,170 | 0 |
| BlackRock, Inc. | 2,849,077 | +581,321 |
| Cormorant Asset Management, LP | 2,390,605 | -500,000 |
| Sofinnova Investments, Inc. | 2,293,788 | 0 |
| Jupiter Topco LLC | 2,144,633 | new |
| Octagon Capital Advisors LP | 1,748,000 | 0 |
| RA Capital Management, L.P. | 1,671,648 | +21,000 |
| Mpm Bioimpact LLC | 1,667,661 | new |
| Vanguard Capital Management LLC | 1,544,214 | +189,308 |
| Polar Capital Holdings Plc | 1,072,344 | -60,296 |
| Braidwell LP | 1,033,129 | -167,458 |
| State Street Corp | 1,021,464 | +170,570 |
| Geode Capital Management, LLC | 1,004,264 | +254,998 |
| Sands Capital Alternatives, LLC | 786,353 | 0 |
| Orbimed Advisors LLC | 752,153 | +40,342 |
| D. E. Shaw & Co., Inc. | 742,761 | +43,571 |
| Balyasny Asset Management L.P. | 702,858 | -624,687 |
| Pivotal bioVenture Partners Investment Advisor LLC | 653,374 | 0 |
| Cosmic Management, LLC | 501,833 | 0 |
| Stempoint Capital LP | 464,171 | -213,137 |
Insiders
2 insiders reported holding 1,013,524 shares in total, about $5.9M at the last price.
| Holder | Shares |
|---|---|
| Fortney KristenChief Executive Officer, Director | 976,949 |
| Goldstein Dov A MdChief Financial Officer | 36,575 |
Questions about BIOA
What does BioAge Labs, Inc. do?
BioAge Labs, Inc. is a company in the Health care sector, listed on NASDAQ as BIOA. Its shares trade on NASDAQ under the ticker BIOA.
What is BioAge Labs, Inc.'s net worth?
BioAge Labs, Inc. has a market value (market cap) of $261.2M at the latest share price, and shareholders' equity of $346.4M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is BioAge Labs, Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $107.8M on revenue of $8.6M.
How much revenue does BioAge Labs, Inc. make?
Over the twelve months to September 30, 2026 BioAge Labs, Inc. reported revenue of $8.6M.
When did BioAge Labs, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 5, 2026. It covers the period to September 30, 2026.
When is BioAge Labs, Inc.'s next earnings report?
BioAge Labs, Inc.'s next report is expected around March 23, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BIOA with
Follow BIOA
Get an email when BioAge Labs, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values BioAge Labs, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.